BusinessAbeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten DiseaseBy Nasdaq OMXApr 20, 2018, 12:15 PM UTC
BusinessAbeona Therapeutics Receives FDA Rare Pediatric Disease Designation for ABO-202 Gene Therapy Program in CLN1 DiseaseBy Nasdaq OMXMar 15, 2018, 12:45 PM UTC
BusinessAbeona Therapeutics Receives FDA Orphan Drug Designation for ABO-202 Gene Therapy Program in Infantile Batten DiseaseBy Nasdaq OMXFeb 12, 2018, 1:45 PM UTC
BusinessAbeona Reports Third Quarter 2017 Financial Results and Recent Business HighlightsBy Nasdaq OMXNov 15, 2017, 1:25 PM UTC
BusinessAbeona Therapeutics Receives FDA Orphan Drug Designation for ABO-201 Juvenile Batten Disease Gene Therapy ProgramBy Nasdaq OMXJun 29, 2017, 12:15 PM UTC
BusinessAbeona Announces Rare Disease Gene Therapy Symposium with the New York Academy of SciencesBy Nasdaq OMXApr 5, 2017, 11:43 AM UTC
